Cantargia AB (publ) (STO:CANTA)

Market Cap	405.24M
Revenue (ttm)	n/a
Net Income (ttm)	-161.65M
Shares Out	248.61M
EPS (ttm)	-0.88
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	389,820
Average Volume	315,880
Open	1.550
Previous Close	1.550
Day's Range	1.550 - 1.650
52-Week Range	1.142 - 5.200
Beta	1.90
RSI	59.79
Earnings Date	May 13, 2025

About Cantargia AB

Cantargia AB (publ), a biotechnology company, develops pharmaceuticals for treatment of cancer, inflammatory, and autoimmune diseases. The company is developing CAN04 (nadunolimab), an antibody that can bind IL1RAP, which is in phase II clinical trial for the treatment of pancreatic cancer, non-small cell lung cancer, and triple-negative breast cancer; and CAN10, an antibody against IL1RAP, which is in phase 1 clinical trial for the treatment of autoimmune and inflammatory diseases, including systemic sclerosis and myocarditis. It also develops...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2009
• Employees: 22
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: CANTA